The proprietary Hemostemix technology relates to a population of cells (the SCP) derived from a simple blood draw, the process for isolating those cells, and then the enrichment and differentiation of those cells into various cell lineages.  The end product is a one or more syringes containing a fresh mixture of cells. 

Our team has been able to take advantage of the potential of this cell population and differentiate it into a variety of cell types including what we call Angiogenic Cell Precursors (cells capable of forming and/or supporting the formation of new blood vessels). 

ACPs are characterized by similar features as Endothelial Progenitor Cells (EPCs). However, as ACPs induce the formation of blood vessels by a variety of means, they are not limited to being building blocks. In addition, ACPs secrete tissue survival and regeneration-supporting growth factors and cytokines, which also facilitate the mobilization of additional progenitor cells and other important elements involved in the healing process of the damaged area.

ACPs facilitate the formation of new blood vessels de-novo by vasculogenesis, or from pre-existing blood vessels by angiogenesis.

We have now successfully completed three clinical trials with ACP-01, one in angina pectoris and two in critical limb ischemia.  Additionally, between 2005 and 2009 the product was used on a compassionate basis for the treatment of several hundred patients with no reports of adverse effects or safety concerns.